References: B

• Babbitt, R. L., J. M. Parrish, P. E. Brierley, and M. A. Kohr. 1991. Teaching developmentally disabled children with chronic illness to swallow prescribed capsules. J. Dev. Behav. Pediatr. 12:229-235.

• Bailey, D. B., D. D. Hatton, and M. Skinner. 1998. Early developmental trajectories of males with fragile X syndrome. Am. J. Ment. Retard. 103:29-39.

• Ban, T. A. 1995. Psychopharmacology and successful cerebral aging. Prog. Neuropsychopharmacol. Biol. Psychiatry 19:1-9.

• Barkley, R. A. 1995. Taking charge of ADHD: The complete, authoritative guide for parents. New York: Guilford Press.

• ---. 1997. ADHD and the nature of self control. New York: Guilford Press.

• ---. 1998. Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment, 2d ed. New York: Guilford Press.

• Barkley, R. A., G. J. DuPaul, and M. B. McMurray. 1991. Attention deficit disorder with and without hyperactivity: Clinical response to three dose levels of methylphenidate. Pediatrics 87:519-531.

• Barrickman, L., R. Noyes, S. Kuperman, E. Schumacher, and M. Verda. 1991. Treatment of ADHD with fluoxetine: A preliminary trial. J. Am. Acad. Child Adolesc. Psychiatry 30:762-766.

• Barrickman, L. L., P. J. Perry, A. J. Allen, S. Kuperman, S. V. Arndt, K. J. Herrmann, and E. Schumacher. 1995. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 34:649-657.

• Beasley, C. M., B. E. Dornself, J. C. Bosomworth, M. E. Sayler, A. H. Rampsey, J. H. Heiligenstein, V. L. Thompson, and D. N. Mason. 1991. Fluoxetine and suicide: A meta analysis of controlled trials of treatment for depression. Br. Med. J. 303:685-692.

• Bellman, B., L. A. Schachner, L. Pravder, S. McFalls, and B. Shapiro. 1995. Carbamazepine hypersensitivity. J. Am. Acad. Child Adolesc. Psychiatry 34:1405-1406.

• Bennett, J., W. T. Goldman, and T. Suppes. 1997. Gabapentin for treatment of bipolar and schizoaffective disorders [letter]. J. Clin. Psychopharmacol. 17:141-142.

• Berkheimer, J. L., J. L. Curtis, and M. W. Lann. 1985. Use of carbamazepine in psychiatric disorders. Clin. Pharm. 4:425-434.

• Berry-Kravis, E. 2000. Medication use in fragile X. Presented at the Seventh International Fragile X Foundation Conference, Los Angeles, July 19-22.

• Binstock, T. 1995. Fragile X and the amygdala: Cognitive, interpersonal, emotional, and neuroendocrine considerations. Dev. Brain Dysfunct. 8:199-217.

• Birmaher, B., G. S. Waterman, N. Ryan, M. Cully, L. Balach, J. Ingram, and M. Brodsky. 1994. Fluoxetine for childhood anxiety disorders. J. Am. Acad. Child Adolesc. Psychiatry 33:993-999.

• Black, B., and T. W. Uhde. 1994. Treatment of elective mutism with fluoxetine: A double-blind, placebo-controlled study. J. Am. Acad. Child Adolesc. Psychiatry 33:1000-1006.

• Blacklidge, V., and R. L. Ekblad. 1971. The effectiveness of methylphenidate hydrochloride (Ritalin) on learning and behavior in public-school educable mentally retarded children. Pediatrics 47:923-926.

• Blackwell, B., and J. Currah. 1973. The psychopharmacology of nocturnal enuresis. In I. Kalvin, R. C. MacKeith, and S. R. Meadow (eds.), Bladder control and enuresis. London: Heinemann, pp. 231-257.

• Blum, N. J., R. S. Kell, H. L. Starr, W. L. Lender, K. L. Bradley-Klug, M. L. Osborne, and P. W. Dowrick. 1998. Case study: Audio feedforward treatment of selective mutism. J. Am. Acad. Child Adolesc. Psychiatry 37:40-43.

• Boccia, M. L., and J. E. Roberts. 2000. Behavior and autonomic nervous system function assessed via heart period measures: The case of hyperarousal in boys with fragile X syndrome. Behav. Res. Methods Instruments Computers 32:5-10.

• Bodfish, J. W., and J. T. Maddison. 1993. Diagnosis and fluoxetine treatment of compulsive behavior disorder of adults with mental retardation. Am. J. Ment. Retard. 98:360-367.

• Bodine, C., J. Sandstrum, J. L. Hills, K. Riley, L. Gane, and R. J. Hagerman. 2001. Vocational use of assistive technology for young adults with fragile X syndrome (submitted).

• Borison, R. L., and J. M. Davis. 1983. Amantadine in Tourette syndrome. Curr. Psychiatr. Ther. 20:127-130.

• Bouchard, R. H., E. Pourcher, and P. Vincent. 1989. Fluoxetine and extrapyramidal side effects [letter]. Am. J. Psychiatry 146:1352-1353.

• Bowden, C. L., A. M. Brugger, A. C. Swann, J. R. Calabrese, P. G. Janicak, F. Petty, S. C. Dilsaver, J. M. Davis, A. J. Rish, J. G. Small, E. S. Garza-Trevino, S. C. Risch, P. J. Goodnick, and D. D. Morris. 1994. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 271:918-924.

• Bowley, C., and M. Kerr. 2000. Epilepsy and intellectual disability. J. Intellect. Disabil. Res. 44:529-543.

• Braden, M. L. 2000a. Fragile X, handle with care: More about fragile X syndrome--adolescents and adults. Dillon, Colo.: Spectra Publishing Co.

• ---. 2000b. Education. In J. Weber (ed.), Children with fragile X syndrome: A parent's guide. Bethesda, Md.: Woodbine House, pp. 243-305.

• Bradley, C. 1937. The behavior of children receiving benzedrine. Am. J. Psychiatry 94:557-585.

• Bregman, J. D. 1991. Current developments in understanding mental retardation: Part II. Psychopathology. J. Am. Acad. Child. Adolesc. Psychiatry 30:861-872.

• Brondum-Nielsen, K., N. Tommerup, B. Frilis, K. Hjelt, and E. Hippe. 1983. Folic acid metabolism in a patient with fragile X. Clin. Genet. 24:153-155.

• Brown, J., M. Braden, and W. Sobesky. 1991. The treatment of behavior and emotional problems. In R. J. Hagerman and A. C. Silverman (eds.), Fragile X syndrome: Diagnosis, treatment, and research. Baltimore: Johns Hopkins Univ. Press, pp. 311-326.

• Brown, J. L. 1995. Imagination training: A tool with many uses. Contemp. Pediatr. 12:22-36.

• Brown, W. T., E. C. Jenkins, E. Friedman, J. Brooks, I. L. Cohen, C. Duncan, A. L. Hill, M. N. Malik, V. Morris, E. Wolf, K. Wisniewski, and J. H. French. 1984. Folic acid therapy in the fragile X syndrome. Am. J. Med. Genet. 17:289-297.

• Brown, W. T., I. L. Cohen, G. S. Fisch, E. Wolf, V. A. Jenkins, M. N. Milik, and E. C. Jenkins. 1986. High dose folic acid treatment of fragile(X) males. Am. J. Med. Genet. 23:263-271.

• Budman, C. L., M. Sherling, and R. D. Bruun. 1995. Combined pharmacotherapy risk [letter]. J. Am. Acad. Child Adolesc. Psychiatry 34:263-264.

• Buitelaar, J. K., R. J. van der Gaag, and J. van der Hoeven. 1998. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: Results of an open-label study. J. Clin. Psychiatry 59:56-59.

• Bukstein, O. G., and D. J. Kolko. 1998. Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder. J. Clin. Child Psychol. 27:340-351.

Buzan, R. D., D. Firestone, M. Thomas, and S. L. Dubovsky. 1995. Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. J. Clin. Psychiatry 56:529-532.

This article is not intended to give medical advice for individual cases.  Any change in medical treatment should be done in consultation with appropriate medical personnel. This article is written for medical professionals.  Some of the terms will be unfamiliar to those who are not trained in medical fields. *This article is from the chapter on treatment in the 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research edited by Randi Jenssen Hagerman, M.D. and Paul Hagerman, M.D., Ph.D., to be published May 2002.  It is included with permission from The Johns Hopkins University Press. References to other chapters refer to chapters in the book which are not included as part of this website. The complete 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research can be ordered from the National Fragile X Foundation by calling 1-800-688-8765 or from The Johns Hopkins University Press at 1-800-537-5487.

Medical Follow-up   Pharmacotherapy   Future Prospects
Outline   Medications   Medical Conditions
References: A, B, C, D, EF, G, H, IJ, K, L, M, NOP, QR, S, T, UVWXYZ
 

© copyright 1998-2008 NFXF